MedDataX Logo

Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

NCT00233532 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2008-07-22

No results posted yet for this study

Summary

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

Conditions

  • Hypertension

Interventions

DRUG

Trandolapril

0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).

Sponsors & Collaborators

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Global Medical Information 1-800-633-9110 · Abbott

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2005-06-30

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00233532 on ClinicalTrials.gov